JP2017522886A - ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用 - Google Patents

ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用 Download PDF

Info

Publication number
JP2017522886A
JP2017522886A JP2017504353A JP2017504353A JP2017522886A JP 2017522886 A JP2017522886 A JP 2017522886A JP 2017504353 A JP2017504353 A JP 2017504353A JP 2017504353 A JP2017504353 A JP 2017504353A JP 2017522886 A JP2017522886 A JP 2017522886A
Authority
JP
Japan
Prior art keywords
antibody
htt
seq
amino acid
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017504353A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522886A5 (enExample
Inventor
メイヤー，マーセル
グリム，ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurimmune Holding AG
Original Assignee
Neurimmune Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurimmune Holding AG filed Critical Neurimmune Holding AG
Publication of JP2017522886A publication Critical patent/JP2017522886A/ja
Publication of JP2017522886A5 publication Critical patent/JP2017522886A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
JP2017504353A 2014-07-29 2015-07-29 ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用 Pending JP2017522886A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14179004.8 2014-07-29
EP14179004 2014-07-29
PCT/EP2015/067327 WO2016016278A2 (en) 2014-07-29 2015-07-29 Human-derived anti-huntingtin (htt) antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020096056A Division JP7235939B2 (ja) 2014-07-29 2020-06-02 ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用

Publications (2)

Publication Number Publication Date
JP2017522886A true JP2017522886A (ja) 2017-08-17
JP2017522886A5 JP2017522886A5 (enExample) 2018-10-18

Family

ID=51225442

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017504353A Pending JP2017522886A (ja) 2014-07-29 2015-07-29 ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用
JP2020096056A Active JP7235939B2 (ja) 2014-07-29 2020-06-02 ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用
JP2023006564A Active JP7562168B2 (ja) 2014-07-29 2023-01-19 ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020096056A Active JP7235939B2 (ja) 2014-07-29 2020-06-02 ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用
JP2023006564A Active JP7562168B2 (ja) 2014-07-29 2023-01-19 ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用

Country Status (11)

Country Link
US (3) US10556946B2 (enExample)
EP (2) EP4406549A3 (enExample)
JP (3) JP2017522886A (enExample)
KR (1) KR102643395B1 (enExample)
CN (2) CN113651887A (enExample)
AU (3) AU2015295441B2 (enExample)
CA (1) CA2954738A1 (enExample)
EA (1) EA201790165A1 (enExample)
IL (2) IL250180A0 (enExample)
MX (3) MX391037B (enExample)
WO (1) WO2016016278A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
US10556946B2 (en) * 2014-07-29 2020-02-11 Neurimmunie Holding AG Human derived anti-Huntingtin (HTT) antibodies and uses thereof
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
MX2020001855A (es) 2017-08-22 2020-08-13 Biogen Ma Inc Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
TW202110878A (zh) 2019-05-16 2021-03-16 法商賽諾菲公司 在神經系統中表現抗原結合蛋白
AU2020363372A1 (en) 2019-10-07 2022-05-19 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
US20230067811A1 (en) 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2022020680A1 (en) 2020-07-23 2022-01-27 Othair Prothena Limited Anti-abeta antibodies
CN111909265B (zh) * 2020-08-25 2022-02-11 中国人民解放军军事科学院军事医学研究院 一种结合破伤风毒素重链c端结构域的人源抗体及应用
AU2022211971A1 (en) 2021-01-29 2023-08-10 Illimis Therapeutics, Inc. Fusion molecule having non-inflammatory phagocytosis inducing activity
CA3239708A1 (en) 2021-12-03 2023-06-08 Aubin MICHALON Novel potency assay for antibody-based drugs and useful means therefor
CN114334076B (zh) * 2021-12-23 2025-03-21 华中科技大学 一种药食同源中药玉竹的重金属概率风险评估方法及系统
WO2024121347A1 (en) * 2022-12-07 2024-06-13 Alchemab Therapeutics Ltd Anti-huntingtin antibodies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232052A1 (en) * 2002-01-28 2003-12-18 Ali Khoshnan Antibodies that bind to an epitope on the Huntington's disease protein
WO2005052002A2 (en) * 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
JP2010514454A (ja) * 2007-01-05 2010-05-06 ユニバーシティ・オブ・チューリッヒ 疾病に特異的な結合分子および標的を提供する方法
WO2016005547A1 (en) * 2014-07-10 2016-01-14 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington's disease
WO2016005545A1 (en) * 2014-07-10 2016-01-14 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington's disease

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
JP3319594B2 (ja) 1990-03-20 2002-09-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 定常領域の代わりに受容体結合性リガンドを有するキメラ抗体
DK0574395T3 (da) 1990-11-09 2002-10-07 Stephen D Gillies Cytokin-immunkonjugater
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
DE669986T1 (de) 1992-11-13 1996-10-10 Idec Pharma Corp Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2116280A1 (en) 1993-03-05 1994-09-06 Marcy E. Macdonald Huntingtin dna, protein and uses thereof
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US6255455B1 (en) * 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
WO1998041645A1 (en) 1997-03-14 1998-09-24 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
DE69834193T2 (de) 1997-08-01 2007-04-19 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur bestimmung von amyloid-ähnlichen fibrillen oder proteinaggregaten
WO2000030680A1 (en) 1998-11-23 2000-06-02 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
EP1204674A4 (en) * 1999-07-27 2005-06-01 Abgenix Inc METHODS AND COMPOUNDS FOR PREVENTING POLYPEPTIDE COLLECTIONS ASSOCIATED WITH NEUROLOGICAL DISORDERS
AU2001297872B2 (en) 2000-11-17 2006-11-09 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
NZ545176A (en) 2001-01-29 2008-05-30 Biogen Idec Inc Modified antibodies reactive with CD20 and methods of use
EP1392849B2 (en) * 2001-02-15 2012-01-18 University Of Chicago Yeast screens for agents affecting protein folding
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
AU2004239114B2 (en) * 2003-05-14 2008-03-13 Japan Science And Technology Agency Inhibition of the expression of huntingtin gene
CA2536408A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US8022268B2 (en) * 2007-06-11 2011-09-20 The University Of Zurich Transgenic animal model for alzheimer's disease
ES2544569T3 (es) 2008-12-19 2015-09-01 Biogen International Neuroscience Gmbh Autoanticuerpos humanos anti alfa-sinucleina
MX345092B (es) 2010-10-11 2017-01-17 Univ Zuerich Anticuerpos anti-tau humanos,.
CA2818781C (en) 2010-12-17 2019-10-08 Neurimmune Holding Ag Human anti-sod1 antibodies
US20140044644A1 (en) 2011-02-21 2014-02-13 University Of Zurich Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
EP2734234A4 (en) * 2011-07-20 2015-01-28 Medimmune Ltd ANTI-CXCR4 ANTIBODIES AND METHOD OF USE THEREOF
AU2012327211C9 (en) 2011-10-28 2016-11-17 Biogen International Neuroscience Gmbh TDP-43 specific binding molecules
CA2913418C (en) * 2013-05-29 2021-11-23 Vybion, Inc. Single chain intrabodies that alter huntingtin mutant degradation
US10556946B2 (en) 2014-07-29 2020-02-11 Neurimmunie Holding AG Human derived anti-Huntingtin (HTT) antibodies and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232052A1 (en) * 2002-01-28 2003-12-18 Ali Khoshnan Antibodies that bind to an epitope on the Huntington's disease protein
WO2005052002A2 (en) * 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
JP2010514454A (ja) * 2007-01-05 2010-05-06 ユニバーシティ・オブ・チューリッヒ 疾病に特異的な結合分子および標的を提供する方法
WO2016005547A1 (en) * 2014-07-10 2016-01-14 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington's disease
WO2016005545A1 (en) * 2014-07-10 2016-01-14 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington's disease

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
BUTLER, D.C. AND MESSER, A., PLOS ONE, vol. 6, no. 12, JPN6018024768, 2011, pages 29199 - 1, ISSN: 0003827415 *
BUTLER, D.C. ET AL., PROG. NEUROBIOL., vol. 97, JPN6018024763, 2012, pages 190 - 204, ISSN: 0003827410 *
COLBY, D.W. ET AL., J. MOL. BIOL., vol. 342, JPN6018024762, 2004, pages 901 - 912, ISSN: 0003827409 *
COLBY, D.W. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 101, no. 51, JPN6018024767, 2004, pages 17616 - 17621, ISSN: 0003827414 *
HUANG, L. ET AL., INT. J. MOL. SCI., vol. 14, JPN6019007541, 2013, pages 19109 - 19127, ISSN: 0003990509 *
IIZUKA, A. ET AL., IMMUNOLOGY LETTERS, vol. 159, JPN6020007542, 15 February 2014 (2014-02-15), pages 15 - 22, ISSN: 0004224527 *
KHOSHNAN, A. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 99, JPN6019007544, 2002, pages 1002 - 1007, ISSN: 0003990512 *
KHOSHNAN, A. ET AL., TRINUCLEOTIDE REPEAT PROTOCOLS, METHODS IN MOLECULAR BIOLOGY, vol. 1010, JPN6018024764, 2013, pages 231 - 251, ISSN: 0003827411 *
KLEIN, U. ET AL., IMMUNOL. REV., vol. 162, JPN6020005578, 1998, pages 261 - 280, ISSN: 0004224528 *
LECERF, J.-M. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 98, no. 8, JPN6018024770, 2001, pages 4764 - 4769, ISSN: 0003827417 *
MESSER, A. AND JOSHI, S.N., NEUROTHERAPEUTICS, vol. 10, JPN6019007543, 2013, pages 447 - 458, ISSN: 0003990513 *
SHEETS, M.D. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, JPN6018024771, 1998, pages 6157 - 6162, ISSN: 0003827418 *
SOUTHWELL, A.L. ET AL., J. NEUROSCI., vol. 28, no. 36, JPN6018024765, 2008, pages 9013 - 9020, ISSN: 0003827412 *
SOUTHWELL, A.L. ET AL., J. NEUROSCI., vol. 29, no. 43, JPN6018024766, 2009, pages 13589 - 13602, ISSN: 0003827413 *
WIENS, G.D. ET AL., J. IMMUNOL., vol. 159, JPN6018017632, 1997, pages 1293 - 1302, ISSN: 0003990511 *
WOLFGANG, W.J. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 102, no. 32, JPN6018024769, 2005, pages 11563 - 11568, ISSN: 0003827416 *

Also Published As

Publication number Publication date
MX2022003704A (es) 2022-04-26
CA2954738A1 (en) 2016-02-04
EP3174898A2 (en) 2017-06-07
KR20170036785A (ko) 2017-04-03
AU2020217427A1 (en) 2020-09-03
IL276721A (en) 2020-09-30
AU2015295441B2 (en) 2020-05-14
JP2021003100A (ja) 2021-01-14
US20170166631A1 (en) 2017-06-15
JP2023052519A (ja) 2023-04-11
CN113651887A (zh) 2021-11-16
MX2022003706A (es) 2022-04-26
AU2020217427B2 (en) 2023-10-19
AU2024200315A1 (en) 2024-02-08
CN107074937A (zh) 2017-08-18
JP7235939B2 (ja) 2023-03-09
IL250180A0 (en) 2017-03-30
WO2016016278A2 (en) 2016-02-04
EP4406549A2 (en) 2024-07-31
EP4406549A3 (en) 2025-01-08
KR102643395B1 (ko) 2024-03-11
US20220332808A1 (en) 2022-10-20
NZ728372A (en) 2021-11-26
WO2016016278A3 (en) 2016-03-24
US10556946B2 (en) 2020-02-11
CN107074937B (zh) 2021-07-27
EA201790165A1 (ru) 2017-07-31
MX2017001285A (es) 2017-04-25
JP7562168B2 (ja) 2024-10-07
US11401325B2 (en) 2022-08-02
AU2015295441A1 (en) 2017-02-02
MX391037B (es) 2025-03-21
US20200392217A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
JP7562168B2 (ja) ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用
JP6841449B2 (ja) トランスサイレチン（ｔｔｒ）アミロイドーシスに対する抗体療法及びそのためのヒト由来抗体
US10961322B2 (en) Human-derived anti-dipeptide repeats (DPRs) antibody
JP6225189B2 (ja) ヒト膵島アミロイドポリペプチド（ｈＩＡＰＰ）特異的抗体およびその使用
EA046697B1 (ru) Происходящие от человека антитела к гентингтину (htt) и их применение
NZ728372B2 (en) Human-derived anti-huntingtin (htt) antibodies and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180629

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20180908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190524

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20190830

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200303

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20200528